Patents by Inventor Neil O'BRIEN

Neil O'BRIEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250051437
    Abstract: The present disclosure provides antigen-binding proteins which bind to CDH17; bispecific antigen-binding proteins which bind to CDH17 and a second antigen; and conjugates thereof. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
    Type: Application
    Filed: December 7, 2022
    Publication date: February 13, 2025
    Inventors: Dennis Slamon, Martina S. McDermott, Neil A. O'Brien
  • Publication number: 20250042992
    Abstract: The present disclosure provides antigen-binding proteins which bind to DLK1; bispecific antigen-binding proteins which bind to DLK1 and a second antigen; and conjugates thereof. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
    Type: Application
    Filed: December 7, 2022
    Publication date: February 6, 2025
    Inventors: Dennis Slamon, Martina S. McDermott, Neil A. O'Brien
  • Patent number: 12205696
    Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.
    Type: Grant
    Filed: October 31, 2022
    Date of Patent: January 21, 2025
    Assignee: Pop Test Abuse Deterrent Technology LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
  • Publication number: 20240400674
    Abstract: The present disclosure provides antigen-binding proteins which bind to Claudin 4 and Claudin 9. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
    Type: Application
    Filed: December 19, 2023
    Publication date: December 5, 2024
    Inventors: Dylan Conklin, Dennis Slamon, Neil A. O'Brien, Michael J. Palazzolo, Erika Von Euw
  • Publication number: 20240390374
    Abstract: The present disclosure provides a method of using mocetinostat in combination with vinorelbine to treating a patient with rhabdomyosarcoma (RMS). The patient can be a child, an adolescent, or an adult having a locally advanced RMS, an unresectable RMS, a metastatic RMS, or a recurrent RMS.
    Type: Application
    Filed: July 22, 2024
    Publication date: November 28, 2024
    Applicant: The Regents of the University of California
    Inventors: Arun Sayram SINGH, Noah FEDERMAN, Dennis Joseph SLAMON, Neil O'BRIEN
  • Publication number: 20240390511
    Abstract: Described herein are methods for inhibiting a solid tumor expressing claudin-6 in a human subject, comprising administering to the human subject an effective amount of a composition comprising conjugates of a CLDN6-specific antigen-binding protein covalently bound to heterologous moieties comprising structural formula (I): wherein a first plurality of the conjugates are bound to four heterologous moieties comprising structural formula (I); at least about 95% of the first plurality of conjugates are structurally homogenous; and the effective amount is in a range of about 1.0 mg of conjugate/kg weight of the subject to 10 mg of conjugate/kg weight of the subject.
    Type: Application
    Filed: May 24, 2024
    Publication date: November 28, 2024
    Inventors: Dennis Slamon, Neil A. O'Brien
  • Patent number: 12065489
    Abstract: The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
    Type: Grant
    Filed: June 22, 2022
    Date of Patent: August 20, 2024
    Assignee: The Regents of the University of California
    Inventors: Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Erika Von Euw, Peter Bowers
  • Patent number: 11834499
    Abstract: The present disclosure provides antigen-binding proteins which bind to Claudin-18.2 (CLDN18.2); bispecific antigen-binding proteins which bind to CLDN18.2 and a second antigen; and conjugates thereof. In various aspects, the antigen-binding proteins bind to Extracellular Loop 1 (EL1) of the extracellular domain of CLDN18.2. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
    Type: Grant
    Filed: October 3, 2022
    Date of Patent: December 5, 2023
    Assignee: The Regents of the University of California
    Inventors: Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon
  • Publication number: 20230116602
    Abstract: The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.
    Type: Application
    Filed: October 2, 2020
    Publication date: April 13, 2023
    Inventors: Brendan M. O' Boyle, Emma L. Baker-Tripp, Corey M. Reeves, Kevin C. Yang, Tristin E. Rose, Justin A. Hilf, Brian M. Stoltz, Michael D. Bartberger, Oliver C. Loson, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon
  • Publication number: 20230049752
    Abstract: The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
    Type: Application
    Filed: June 22, 2022
    Publication date: February 16, 2023
    Inventors: Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Erika Von Euw, Peter Bowers
  • Publication number: 20220372133
    Abstract: The present disclosure provides antigen-binding proteins which bind to Claudin-18.2 (CLDN18.2); bispecific antigen-binding proteins which bind to CLDN18.2 and a second antigen; and conjugates thereof. In various aspects, the antigen-binding proteins bind to Extracellular Loop 1 (EL1) of the extracellular domain of CLDN18.2. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
    Type: Application
    Filed: July 17, 2020
    Publication date: November 24, 2022
    Inventors: Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon
  • Publication number: 20220372134
    Abstract: The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
    Type: Application
    Filed: April 13, 2022
    Publication date: November 24, 2022
    Inventors: Dylan CONKLIN, Dennis Slamon, Neil A. O'Brien, Michael J. Palazzolo, Erika Von Euw
  • Publication number: 20220280510
    Abstract: The present disclosure provides a method of using mocetinostat in combination with vinorelbine to treating a patient with rhabdomyosarcoma (RMS). The patient can be a child, an adolescent, or an adult having a locally advanced RMS, an unresectable RMS, a metastatic RMS, or a recurrent RMS.
    Type: Application
    Filed: March 7, 2022
    Publication date: September 8, 2022
    Applicant: The Regents of the University of California
    Inventors: Arun Sayram SINGH, Noah FEDERMAN, Dennis Joseph SLAMON, Neil O'BRIEN
  • Publication number: 20220227738
    Abstract: The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.
    Type: Application
    Filed: May 20, 2020
    Publication date: July 21, 2022
    Inventors: Justin A. Hilf, Tristin E Rose, Michael D. Bartberger, Brendan M. O'Boyle, Corey M. Reeves, Oliver C. Loson, Brian M. Stoltz, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon
  • Publication number: 20220194949
    Abstract: The present disclosure describes compounds of formulas (I)-(V) and methods of making the same. The compounds of the present disclosure are useful as inhibitors of PRMT5 activity and in methods of treating cancers and other diseases.
    Type: Application
    Filed: March 25, 2020
    Publication date: June 23, 2022
    Inventors: Brendan M. O'Boyle, Corey M. Reeves, Justin A. Hilf, Brian M. Stoltz, Michael D. Bartberger, Steven J. Wittenberger, Oliver C. Loson, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon
  • Publication number: 20220177583
    Abstract: The present disclosure provides bispecific antigen-binding proteins which bind to Claudin-6 (CLDN6) and a second antigen. In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
    Type: Application
    Filed: March 20, 2020
    Publication date: June 9, 2022
    Inventors: Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Erika Von Euw, Peter Bowers
  • Publication number: 20220162299
    Abstract: The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
    Type: Application
    Filed: March 20, 2020
    Publication date: May 26, 2022
    Inventors: Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Erika Von Euw, Peter Bowers
  • Publication number: 20220106325
    Abstract: The present disclosure provides compounds and compositions that are CDK inhibitors selective for CDK4 and/or CDK6, and methods of use thereof.
    Type: Application
    Filed: July 26, 2019
    Publication date: April 7, 2022
    Inventors: Brendan M. O'Boyle, Justin A. Hilf, Scott C. Virgil, Alexander W. Sun, Brian M. Stoltz, Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Michael D. Bartberger
  • Publication number: 20220002294
    Abstract: The present disclosure provides compounds and compositions that are inhibitors of ERK1, ERK2, or both, and methods of use thereof.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 6, 2022
    Inventors: Corey M. Reeves, Brandan M. O'Boyle, Justin A. Hilf, Dylan Conklin, Martina S. McDermott, Neil A. O'Brien, Michael J. Palazzolo, Dennis Slamon, Steven J. Wittenberger, Oliver C. Loson, Michael D. Bartberger, Brian M. Stoltz
  • Publication number: 20200291111
    Abstract: The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.
    Type: Application
    Filed: September 18, 2018
    Publication date: September 17, 2020
    Inventors: Dylan Conklin, Dennis Slamon, Neil A. O'Brien, Michael J. Palazzolo, Erika Von Euw